GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (OSTO:ASAP) » Definitions » EPS (Diluted)

Asarina Pharma AB (OSTO:ASAP) EPS (Diluted) : kr-0.57 (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Asarina Pharma AB EPS (Diluted)?

Asarina Pharma AB's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was kr-0.15. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.57.

Asarina Pharma AB's EPS (Basic) for the six months ended in Dec. 2023 was kr-0.15. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.57.

Asarina Pharma AB's EPS without NRI for the six months ended in Dec. 2023 was kr-0.15. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.57.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Asarina Pharma AB EPS (Diluted) Historical Data

The historical data trend for Asarina Pharma AB's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB EPS (Diluted) Chart

Asarina Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -3.85 -4.02 -1.69 -0.71 -0.57

Asarina Pharma AB Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.49 -0.44 -0.27 -0.42 -0.15

Competitive Comparison of Asarina Pharma AB's EPS (Diluted)

For the Biotechnology subindustry, Asarina Pharma AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Asarina Pharma AB's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Asarina Pharma AB's PE Ratio distribution charts can be found below:

* The bar in red indicates where Asarina Pharma AB's PE Ratio falls into.


;
;

Asarina Pharma AB EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Asarina Pharma AB's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-12.828-0)/22.911
=-0.56

Asarina Pharma AB's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-3.34-0)/22.641
=-0.15

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Asarina Pharma AB  (OSTO:ASAP) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Asarina Pharma AB EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Asarina Pharma AB's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Asarina Pharma AB Business Description

Traded in Other Exchanges
N/A
Address
Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65
Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB Headlines

No Headlines